127 related articles for article (PubMed ID: 35933706)
1. Bioactivity of hamamelitannin, flavokawain A, and triacetyl resveratrol as natural compounds: Molecular docking study, anticolon cancer, and anti-Alzheimer potentials.
Zhang M; Xue J; Chen X; Elsaid FG; Salem ET; Ghanem RA; El-Kott AF; Xu Z
Biotechnol Appl Biochem; 2023 Apr; 70(2):730-745. PubMed ID: 35933706
[TBL] [Abstract][Full Text] [Related]
2. Anti-ovarian cancer potential, in silico studies, and anti-Alzheimer's disease effects of some natural compounds as cholinesterase inhibitors.
Fu M; Ji C; Yang T; Mao F; Shati AA; El-Kott AF; El-Maksoud MMA; Negm S; Ji Y
Biotechnol Appl Biochem; 2023 Jun; 70(3):1085-1099. PubMed ID: 36515452
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation and molecular docking of cyclic biguanidine compounds as cholinesterase inhibitors.
Gungor O; Kose M
J Biomol Struct Dyn; 2023 Dec; 41(20):10885-10899. PubMed ID: 36537267
[TBL] [Abstract][Full Text] [Related]
4. Identification of Natural Compounds of the Apple as Inhibitors against Cholinesterase for the Treatment of Alzheimer's Disease: An In Silico Molecular Docking Simulation and ADMET Study.
Jamal QMS; Khan MI; Alharbi AH; Ahmad V; Yadav BS
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049419
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
[TBL] [Abstract][Full Text] [Related]
6. In silico modeling for dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes in Alzheimer's disease.
Kumar V; Saha A; Roy K
Comput Biol Chem; 2020 Oct; 88():107355. PubMed ID: 32801088
[TBL] [Abstract][Full Text] [Related]
7. Search for new multi-target compounds against Alzheimer's disease among histamine H
Bajda M; Łażewska D; Godyń J; Zaręba P; Kuder K; Hagenow S; Łątka K; Stawarska E; Stark H; Kieć-Kononowicz K; Malawska B
Eur J Med Chem; 2020 Jan; 185():111785. PubMed ID: 31669851
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, In Vitro Biological Evaluation and In Silico Molecular Docking Study of Benzimidazole-Based Oxazole Analogues: A Promising Acetylcholinesterase and Butyrylcholinesterase Inhibitors.
Hussain R; Rahim F; Ullah H; Khan S; Sarfraz M; Iqbal R; Suleman F; Al-Sadoon MK
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894494
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and molecular modelling of thiadizole based hydrazone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitory activities.
Işık A; Acar Çevik U; Karayel A; Celik I; Erçetin T; Koçak A; Özkay Y; Kaplancıklı ZA
SAR QSAR Environ Res; 2022 Mar; 33(3):193-214. PubMed ID: 35243936
[TBL] [Abstract][Full Text] [Related]
10. Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors.
Daoud I; Melkemi N; Salah T; Ghalem S
Comput Biol Chem; 2018 Jun; 74():304-326. PubMed ID: 29747032
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Biological Evaluation and Molecular Docking Study of Hydrazone-Containing Pyridinium Salts as Cholinesterase Inhibitors.
Parlar S; Bayraktar G; Tarikogullari AH; Alptüzün V; Erciyas E
Chem Pharm Bull (Tokyo); 2016; 64(9):1281-7. PubMed ID: 27581632
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological activity of novel tacrine-isatin Schiff base hybrid derivatives.
Riazimontazer E; Sadeghpour H; Nadri H; Sakhteman A; Tüylü Küçükkılınç T; Miri R; Edraki N
Bioorg Chem; 2019 Aug; 89():103006. PubMed ID: 31158577
[TBL] [Abstract][Full Text] [Related]
13. Multi-target approach for Alzheimer's disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4-
Adeowo FY; Ejalonibu MA; Elrashedy AA; Lawal MM; Kumalo HM
J Biomol Struct Dyn; 2021 Jul; 39(11):3825-3841. PubMed ID: 33030113
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and preliminary structure-activity relationship investigation of nitrogen-containing chalcone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors: a further study based on Flavokawain B Mannich base derivatives.
Liu H; Fan H; Gao X; Huang X; Liu X; Liu L; Zhou C; Tang J; Wang Q; Liu W
J Enzyme Inhib Med Chem; 2016 Aug; 31(4):580-9. PubMed ID: 26186269
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterisation, DNA binding, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and molecular docking studies of metal(II) complexes with 1,10-phenanthroline scaffold.
Gladis EHE; Nagashri K; Anisha M; Joseph J
J Biomol Struct Dyn; 2023 Jul; 41(11):5067-5085. PubMed ID: 35699274
[TBL] [Abstract][Full Text] [Related]
16. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J
Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of Novel Dual Cholinesterase Inhibitors: In Vitro Inhibition Studies Supported with Molecular Docking.
Koca M; Güller U; Güller P; Dağalan Z; Nişancı B
Chem Biodivers; 2022 Jun; 19(6):e202200015. PubMed ID: 35470963
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity.
Guan L; Peng D; Zhang L; Jia J; Jiang H
Bioorg Med Chem Lett; 2021 Nov; 52():128306. PubMed ID: 34371131
[TBL] [Abstract][Full Text] [Related]
19. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti-Alzheimer's agents.
Shamsimeymandi R; Pourshojaei Y; Eskandari K; Mohammadi-Khanaposhtani M; Abiri A; Khodadadi A; Langarizadeh A; Sharififar F; Amirheidari B; Akbarzadeh T; Lotfian H; Foroumadi A; Asadipour A
Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800352. PubMed ID: 31136018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
